Raltegravir
Raltegravir has been studied in 5 papers since 2016: 4 trials in people, 1 in cells. The newest paper, Jul 20, 2021: “Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial”.
See all 9 papers on raltegravir
At a glance
The findings reach people, from one lab or study. 3 independent labs in 1 country; 17 trials, none about aging, 4 with no results posted.
“There were no significant differences in the ART effect on epigenetic ageing between treatment regimens.”
None of its findings points the other way.
- 3 independent labs in 1 country
- 17 trials, none about aging, 4 with no results posted
- Funders: Gilead Sciences and 6 more
- 2 of 6 findings with company ties
- Human trial4
- Cells1
Studies in people
3 studies gave raltegravir to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases activated T lymphocytesCD4+CD38+HLA-DR+ -0.3 vs 0.48 (P = 0.033); CD8+CD38+HLA-DR+ -1.6 vs 1.3 (P = 0.02) down: Decreases senescent T lymphocytesCD4+CD28-CD57+ -0.3 vs 0.26 (P = 0.04); CD8+CD28-CD57+ -6.1 vs 3.8 (P = 0.002) up: Increases CD4/CD8 ratiomedian +0.35 vs +0.03 in other arms | Randomized trial48 weeks | 48 people | HIV medicine, Jul 20, 2021 |
no change: Has no effect on epigenetic age | Randomized trial2 years | 168 peoplePatient cohorts | The lancet. HIV, Apr 1, 2021 |
down: Decreases CD38+ CD8+ T cells up: Increases CD28- CD57+ T cells | Randomized trial24 weeks | 42 people≥40 yearsMidlife adults; switch from protease inhibitor to raltegravir | PloS one, Sep 17, 2020 |
What did studies of raltegravir find?
6Studies of raltegravir measured 6 outcomes, among them CD4/CD8 ratio, Senescent T lymphocytes and Activated T lymphocytes.
CD4/CD8 ratio
upin humans1
1 study
CD4/CD8 ratio
upin humans1
Raltegravir increases CD4/CD8 ratio in humans (median +0.35 vs +0.03 in other arms).
“the median CD4/CD8 ratio increased by 0.35 in patients in the raltegravir group vs. 0.03 in the other arms (P = 0.002)”
Human trial48 weeks
HIV medicine
Senescent T lymphocytes
downin humans1
1 study
Senescent T lymphocytes
downin humans1
Raltegravir decreases senescent T lymphocytes in humans (CD4+CD28-CD57+ -0.3 vs 0.26 (P = 0.04); CD8+CD28-CD57+ -6.1 vs 3.8 (P = 0.002)).
“switching to a regimen with raltegravir significantly decreased activated and senescent T-lymphocyte subpopulations”
Human trial48 weeks
HIV medicine
Activated T lymphocytes
downin humans1
1 study
Activated T lymphocytes
downin humans1
Raltegravir decreases activated T lymphocytes in humans (CD4+CD38+HLA-DR+ -0.3 vs 0.48 (P = 0.033); CD8+CD38+HLA-DR+ -1.6 vs 1.3 (P = 0.02)).
“patients who switched to raltegravir showed a higher decrease in all activated”
Human trial48 weeks
HIV medicine
Epigenetic age
no changein humans1
1 study
Epigenetic age
no changein humans1
Raltegravir showed no clear effect on epigenetic age in humans.
“There were no significant differences in the ART effect on epigenetic ageing between treatment regimens.”
Human trialcompared with tenofovir disoproxil fumarate/emtricitabine, both combined with ritonavir-boosted darunavirwhole blood2 yearsn = 168
The lancet. HIV
CD28- CD57+ T cells
upin humans1
1 study
CD28- CD57+ T cells
upin humans1
Raltegravir increases CD28- CD57+ T cells in humans (switch from protease inhibitor to raltegravir).
“an increase in the frequency of CD28-CD57+ in both CD4 and CD8 T-cell compartments were noticed in the Raltegravir-switched group”
Human trialswitch from protease inhibitor to raltegravirCD4 and CD8 T cells
PloS one
CD38+ CD8+ T cells
downin humans1
1 study
CD38+ CD8+ T cells
downin humans1
Raltegravir decreases CD38+ CD8+ T cells in humans (switch from protease inhibitor to raltegravir).
“Only a modest decrease in the frequency of CD38+ CD8 T cells”
Human trialswitch from protease inhibitor to raltegravir
PloS one
Trial sponsors
Company3 trialsPhase 41,100 people
Company3 trialsPhase 4321 people
Company5 trialsPhase 3974 people
Company1 trialPhase 3206 people
Company1 trialPhase 333 people
Tibotec Pharmaceuticals, Ireland
Company1 trialPhase 148 people
Company1 trialPhase 136 people
Company1 trialPhase 124 people